Demand for patient monitoring services recovering with revenue increasing 45.5% in first half of 2021
Accelerating growth strategy with expansion of Prizma and Cardiac sales team
UnityPoint Prizma vital signs pilot study to start end of September; new cardiac services program underway
Gainers
Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Following the market opening Wednesday, the Dow traded up 0.13% to 34,621.78 while the NASDAQ fell 0.25% to 14,999.72. The S&P also rose, gaining 0.03% to 4,444.41.